Repurposing of Cetuximab in antibody-directed chemotherapy-loaded nanoparticles in EGFR therapy-resistant pancreatic tumours
Open accessAbstract
The use of CTX as a targeting agent for camptothecin-loaded polymeric nanoparticles directed against KRAS mutant CTX-resistant cancer cells was investigated. CTX increased CPT internalisation into cancer cells resulting in elevated cancer cell death.
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
EGFR is a cell surface receptor expressed in many different types of cells, especially overexpressed in cancer cells.
“EGFR is a cell surface receptor expressed in many different types of cells, especially overexpressed in cancer cells.195”
From Smart nanoparticles for cancer therapy (2023) · cites this paper as [195]
The CTX coupled nano drug delivery system enhanced the ability of NPs to target the cell surface by interacting with EGFR.
“The results confirmed that the CTX coupled nano drug delivery system enhanced the ability of NPs to target the cell surface by interacting with EGFR.195”
From Smart nanoparticles for cancer therapy (2023) · cites this paper as [195]
The overexpression of EGFR is closely related to the differentiation and migration of cancer cells.
“Researchers have shown that the overexpression of EGFR is closely related to the differentiation and migration of cancer cells.”
From Smart nanoparticles for cancer therapy (2023) · cites this paper as [195]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Cites
Whole genomes redefine the mutational landscape of pancreatic cancer
Initiative, A. P. C. G., Waddell, N., Pajic, M., Patch, A.-M., Chang, D. K., Kassahn, K. S., Bailey, P., Johns, A. L., Miller, D., Nones, K., et al. (2015) · Nature · doi:10.1038/nature14169 · Cited by 2,642 · see citing works
Topoisomerase I inhibitors: camptothecins and beyond
Pommier, Y. G. (2006) · Nature reviews. Cancer · doi:10.1038/nrc1977 · Cited by 2,295 · see citing works
<i>KRAS</i> Mutation Status Is Predictive of Response to Cetuximab Therapy in Colorectal Cancer
Lièvre, A., Bachet, J.-B., Le Corre, D., Boige, V., Landi, B., Emile, J.-F., Côté, J.-F., Tomasic, G., Penna, C., Ducreux, M., et al. (2006) · Cancer Research · doi:10.1158/0008-5472.can-06-0191 · Cited by 2,229 · see citing works
Epidermal growth factor receptor (EGFR) signaling in cancer
Normanno, N., Luca, A. D., Bianco, C., Strizzi, L., Mancino, M., Maiello, M. R., Carotenuto, A., Feo, G. D., Caponigro, F., & Salomon, D. S. (2005) · Gene · doi:10.1016/j.gene.2005.10.018 · Cited by 2,035 · see citing works
Emergence of KRAS mutations and acquired resistance to anti-EGFR therapy in colorectal cancer
Misale, S., Yaeger, R., Hobor, S., Scala, E., Janakiraman, M., Liska, D., Valtorta, E., Schiavo, R., Buscarino, M., Siravegna, G., et al. (2012) · Nature · doi:10.1038/nature11156 · Cited by 1,889 · see citing works
Di Nicolantonio, F., Martini, M., Molinari, F., Sartore-Bianchi, A., Arena, S., Saletti, P., De Dosso, S., Mazzucchelli, L., Frattini, M., Siena, S., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2008.18.0786 · Cited by 1,591 · see citing works
Structural basis for inhibition of the epidermal growth factor receptor by cetuximab
Li, S., Schmitz, K. R., Jeffrey, P. D., Wiltzius, J. J. W., Kussie, P. H., & Ferguson, K. M. (2005) · Cancer Cell · doi:10.1016/j.ccr.2005.03.003 · Cited by 1,117 · see citing works
Gao, H., Yang, Z. H., Zhang, S., Cao, S., Shen, S.-Q., Pang, Z., & Jiang, X. (2014) · Scientific Reports · doi:10.1038/srep05138 · Cited by 1,062 · see citing works
Phenotype and Genotype of Pancreatic Cancer Cell Lines
Deer, E. L., González-Hernández, J., Coursen, J. D., Shea, J. E., Ngatia, J., Scaife, C. L., Firpo, M. A., & Mulvihill, S. J. (2010) · Pancreas · doi:10.1097/mpa.0b013e3181c15963 · Cited by 936 · see citing works
Epigenetic and genetic features of 24 colon cancer cell lines
Ahmed, D., Eide, P. W., Eilertsen, I. A., Danielsen, S. A., Eknæs, M., Hektoen, M., Lind, G. E., & Lothe, R. A. (2013) · Oncogenesis · doi:10.1038/oncsis.2013.35 · Cited by 913 · see citing works
KRAS: The Critical Driver and Therapeutic Target for Pancreatic Cancer
Waters, A. M., & Der, C. J. (2018) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a031435 · Cited by 875 · see citing works
Singh, A., Greninger, P., Rhodes, D., Koopman, L., Violette, S., Bardeesy, N., & Settleman, J. (2009) · Cancer Cell · doi:10.1016/j.ccr.2009.03.022 · Cited by 841 · see citing works
Altered Growth of Human Colon Cancer Cell Lines Disrupted at Activated Ki- ras
Shirasawa, S., Furuse, M., Yokoyama, N., & Sasazuki, T. (1993) · Science · doi:10.1126/science.8465203 · Cited by 621 · see citing works
Masui, H., Kawamoto, T., Sato, J., Wolf, B., SATO, G. H., & Mendelsohn, J. M. (1984) · The Journal of Urology · doi:10.1016/s0022-5347(17)50005-1 · Cited by 446 · see citing works
Stintzing, S., Modest, D. P., Rossius, L., Lerch, M. M., von Weikersthal, L. F., Decker, T., Kiani, A., Vehling-Kaiser, U., Al-Batran, S.-E., Heintges, T., et al. (2016) · The Lancet Oncology · doi:10.1016/s1470-2045(16)30269-8 · Cited by 420 · see citing works
Targeted Delivery of Gemcitabine to Pancreatic Adenocarcinoma Using Cetuximab as a Targeting Agent
Patra, C. R., Bhattacharya, R., Wang, E., Katarya, A., Lau, J. S., Dutta, S. K., Muders, M. H., Wang, S., Buhrow, S. A., Safgren, S. L., et al. (2008) · Cancer Research · doi:10.1158/0008-5472.can-07-6102 · Cited by 372 · see citing works
Krop, I. E., LoRusso, P. M., Miller, K. D., Modi, S., Yardley, D. A., Rodriguez, G., Guardino, E., Lu, M. W., Zheng, M., Girish, S., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.40.5902 · Cited by 366 · see citing works
Pizzolato, J. F., & Saltz, L. B. (2003) · The Lancet · doi:10.1016/s0140-6736(03)13780-4 · Cited by 365 · see citing works
Slatter, J. G., Schaaf, L. J., Sams, J. P., Feenstra, K. L., Johnson, M. G., Bombardt, P. A., Cathcart, K. S., Verburg, M. T., Pearson, L. K., Compton, L. D., et al. (2000) · Drug Metabolism and Disposition · doi:10.1016/s0090-9556(24)15060-x · Cited by 302 · see citing works
KRAS oncogene in non-small cell lung cancer: clinical perspectives on the treatment of an old target
Román, M., Baraibar, I., López, I., Nadal, E., Rolfo, C., Vicent, S., & Gil-Bazo, I. (2018) · Molecular Cancer · doi:10.1186/s12943-018-0789-x · Cited by 301 · see citing works
Molecular mechanisms of resistance to the EGFR monoclonal antibody cetuximab
Brand, T. M., Iida, M., & Wheeler, D. L. (2011) · Cancer Biology & Therapy · doi:10.4161/cbt.11.9.15050 · Cited by 275 · see citing works
Masui, H., Kawamoto, T., Sato, J. D., et al. (1984) · PubMed · Cited by 250 · see citing works
Antibody-based therapeutics to watch in 2011
Reichert, J. M. (2011) · mAbs · doi:10.4161/mabs.3.1.13895 · Cited by 236 · see citing works
Weiss, G. J., Chao, J., Neidhart, J. D., Ramanathan, R. K., Bassett, D., Neidhart, J. A., Choi, C. H. J., Chow, W. A., Chung, V. M., Forman, S. J., et al. (2013) · Investigational New Drugs · doi:10.1007/s10637-012-9921-8 · Cited by 234 · see citing works
KRAS mutation testing in metastatic colorectal cancer.
Tan, C., & Du, X. (2012) · PubMed Central · doi:10.3748/wjg.v18.i37.5171 · Cited by 230 · see citing works
Gradiz, R., Silva, H. C., Carvalho, L., Botelho, M. F., & Mota‐Pinto, A. (2016) · Scientific Reports · doi:10.1038/srep21648 · Cited by 174 · see citing works
Antibody-Targeted Nanoparticles for Cancer Therapy
Fay, F., & Scott, C. J. (2011) · Immunotherapy · doi:10.2217/imt.11.5 · Cited by 160 · see citing works
Self-citationPassero, F. C., Grapsa, D., Syrigos, K., & Saif, M. W. (2016) · Expert Review of Anticancer Therapy · doi:10.1080/14737140.2016.1192471 · Cited by 150 · see citing works
Antibody Targeting of Camptothecin-Loaded PLGA Nanoparticles to Tumor Cells
McCarron, P. A., Marouf, W. M., Quinn, D. J., Fay, F., Burden, R. E., Olwill, S. A., & Scott, C. J. (2008) · Bioconjugate Chemistry · doi:10.1021/bc800057g · Cited by 127 · see citing works
Self-citationToda, K., Kawada, K., Iwamoto, M., Inamoto, S., Sasazuki, T., Shirasawa, S., Hasegawa, S., & Sakai, Y. (2016) · Neoplasia · doi:10.1016/j.neo.2016.09.004 · Cited by 113 · see citing works
Qian, Y., Qiu, M., Wu, Q., et al. (2014) · Scientific Reports · doi:10.1038/srep07490 · Cited by 110 · see citing works
Antibody conjugated nanoparticles as a novel form of antibody drug conjugate chemotherapy
Johnston, M. C., & Scott, C. J. (2018) · Drug Discovery Today Technologies · doi:10.1016/j.ddtec.2018.10.003 · Cited by 90 · see citing works
Self-citationMa, C., Wang, F., Han, B., Zhong, X., Si, F., Ye, J., Hsueh, E. C., Robbins, L., Kiefer, S. M., Zhang, Y., et al. (2018) · Molecular Cancer · doi:10.1186/s12943-018-0824-y · Cited by 80 · see citing works
Tan, V. P. (2012) · World Journal of Gastroenterology · doi:10.3748/wjg.v18.i42.6127 · Cited by 79 · see citing works
Epidermal growth factor receptor-targeted immunoliposomes for delivery of celecoxib to cancer cells
Limasale, Y. D. P., Tezcaner, A., Özen, C., Keskin, D. S., & Banerjee, S. (2015) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2015.01.016 · Cited by 64 · see citing works
Chakrabarti, G. (2015) · Radiation Oncology · doi:10.1186/s13014-015-0457-x · Cited by 63 · see citing works
Schmid, D., Jarvis, G. E., Fay, F., Small, D. M., Greene, M. K., Majkut, J., Spence, S., McLaughlin, K. M., McCloskey, K. D., Johnston, P. G., et al. (2014) · Cell Death and Disease · doi:10.1038/cddis.2014.413 · Cited by 56 · see citing works
Self-citationKim, Y., Jung, K., Beak, D., Hong, S.-S., & Kim, Y. (2016) · Oncogene · doi:10.1038/onc.2016.407 · Cited by 53 · see citing works
van Houdt, W. J., Hoogwater, F. J. H., de Bruijn, M. T., Emmink, B. L., Nijkamp, M. W., Raats, D., van der Groep, P., van Diest, P. J., Rinkes, I. H. M. B., & Kranenburg, O. (2010) · Neoplasia · doi:10.1593/neo.92088 · Cited by 49 · see citing works
de Miguel, D., Gallego-Lleyda, A., Anel, A., et al. (2015) · Leukemia Research · doi:10.1016/j.leukres.2015.03.019 · Cited by 48 · see citing works
Huang, Z., Buchsbaum, D. J., Raisch, K. P., et al. (2003) · Journal of Surgical Research · doi:10.1016/s0022-4804(03)00076-3 · Cited by 48 · see citing works
Deepagan, V. G., Sarmento, B. F. C. C., Menon, D., Nascimento, A. V., Jayasree, A., Sreeranganathan, M., Koyakutty, M., Nair, S. V., & Jayakumar, R. (2012) · Nanomedicine · doi:10.2217/nnm.11.139 · Cited by 47 · see citing works
Schmid, D., Fay, F., Small, D. M., Jaworski, J., Riley, J. S., Tegazzini, D., Fenning, C., Jones, D. S., Johnston, P. G., Longley, D. B., et al. (2014) · Molecular Therapy · doi:10.1038/mt.2014.137 · Cited by 45 · see citing works
Self-citationSreeranganathan, M., Uthaman, S., Sarmento, B. F. C. C., Mohan, C. G., Park, I., & Jayakumar, R. (2017) · International Journal of Nanomedicine · doi:10.2147/ijn.s143529 · Cited by 26 · see citing works
Anthony, L. B. (2007) · Current Opinion in Supportive and Palliative Care · doi:10.1097/spc.0b013e328133f2ad · Cited by 13 · see citing works
Novel multifunctional antibody approved for the treatment of breast cancer
Mavilio, D., Galluzzi, L., & Lugli, E. (2013) · OncoImmunology · doi:10.4161/onci.24567 · Cited by 9 · see citing works
Flagged first, then by citations
Cited by
Sorted by citations
Smart nanoparticles for cancer therapy
Sun, L., Liu, H., Ye, Y., Lei, Y., Islam, R., Tan, S., Tong, R., Miao, Y.-B., & Cai, L. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01642-x · Cited by 1,073 · see citing works
- Authors
- McDaid, W. J., Greene, M. K., Johnston, M. C., Pollheimer, E., Smyth, P., McLaughlin, K., Van Schaeybroeck, S., Straubinger, R. M., Longley, D. B., & Scott, C. J.
- Affiliations
- Queen's University Belfast (GB)
- Centre for Cancer Research and Cell Biology
- State University of New York (US)
- Corresponding author
- Scott, Christopher J.
- ORCID
- Venue
- Nanoscale
- Publisher
- Royal Society of Chemistry (RSC)
- Published
- 2019
- Volume
- 11
- Issue
- 42
- Pages
- 20261-20273
- ISSN
- 2040-3364 (ISSN-L)
- 2040-3372
- PMC
- PMC6861736
- OpenAlex
- W2981159739
- Cited by
- 58
- References
- 46
- Citations by year
- 2026: 5 · 2025: 8 · 2024: 9 · 2023: 7 · 2022: 12 · 2021: 9 · 2020: 8
- FWCI
- 2.05
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Nanoscale (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Research Portal (Queen's University Belfast) (submittedVersion, other-oa)
- Funders
- Medical Research Council (MRC grant 1598124, MC_PC_15013)
- National Institutes of Health (R21CA168454, R01CA198096)
- Topics
- Physical Sciences › Materials Science › Biomaterials › Nanoparticle-Based Drug Delivery
- Health Sciences › Medicine › Oncology › Pancreatic and Hepatic Oncology Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA Interference and Gene Delivery
- Keywords
- cetuximab, camptothecin, polymeric nanoparticles, PLGA nanoparticles, EGFR, KRAS mutation, pancreatic cancer, drug resistance, targeted drug delivery, PANC-1 cells, tumor growth inhibition
- MeSH terms
- Cetuximab, Ado-Trastuzumab Emtansine, Animals, Female, Humans, Neoplasm Proteins, Pancreatic Neoplasms, Mice, SCID, Immunoconjugates, Drug Resistance, Neoplasm, Xenograft Model Antitumor Assays, HCT116 Cells, Mice, Nanoparticles, ErbB Receptors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
